Insmed Inc (INSM) concluded trading on Thursday at a closing price of $72.05, with 3.55 million shares of worth about $255.7 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 16.91% during that period and on December 12, 2024 the price saw a loss of about -2.90%. Currently the company’s common shares owned by public are about 178.85M shares, out of which, 174.61M shares are available for trading.
Stock saw a price change of -4.35% in past 5 days and over the past one month there was a price change of 2.72%. Year-to-date (YTD), INSM shares are showing a performance of 132.49% which increased to 157.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $21.92 but also hit the highest price of $80.53 during that period. The average intraday trading volume for Insmed Inc shares is 1.51 million. The stock is currently trading -1.36% below its 20-day simple moving average (SMA20), while that difference is down -0.35% for SMA50 and it goes to 25.33% higher than SMA200.
Insmed Inc (NASDAQ: INSM) currently have 178.85M outstanding shares and institutions hold larger chunk of about 105.29% of that.
The stock has a current market capitalization of $12.89B and its 3Y-monthly beta is at 1.11. It has posted earnings per share of -$5.56 in the same period. It has Quick Ratio of 5.99 while making debt-to-equity ratio of 2.41. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INSM, volatility over the week remained 3.59% while standing at 4.15% over the month.
Stock’s fiscal year EPS is expected to drop by -0.69% while it is estimated to increase by 19.33% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on April 23, 2024 offering a Buy rating for the stock and assigned a target price of $48 to it. Coverage by Wolfe Research stated Insmed Inc (INSM) stock as an Outperform in their note to investors on February 15, 2024, suggesting a price target of $42 for the stock. On December 08, 2023, Wells Fargo Initiated their recommendations, while on November 20, 2023, JP Morgan Resumed their ratings for the stock with a price target of $36. Stock get a Buy rating from Guggenheim on July 26, 2023.
